Toft Group Completes Executive Search for Ascendis Pharma Inc., (NASDAQ: ASND) in Palo Alto, CA
Executive search firm Toft Group has placed Dr. Aimee Shu as the Director, Clinical Development Endocrinology for Ascendis Pharma in Palo Alto, CA. Dr. Shu is a board-certified Endocrinologist who joins Ascendis from Stanford University where she served as Clinical Associate Professor of Medicine and Associate Program Director, Endocrinology Fellowship Training Program. She earned her MD from Harvard Medical School.
About Ascendis Pharma
Ascendis Pharma is applying the TransCon technology platform to build a leading rare disease commercial company. The company utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases by improving clinically validated parent drugs and creating therapies with potential for best-in-class efficacy, safety and/or convenience.
Ascendis Pharma has a wholly-owned pipeline of rare disease endocrinology programs, including once-weekly TransCon Growth Hormone, which is currently being evaluated in the Phase 3 heiGHt Trial for children with growth hormone deficiency (GHD), TransCon PTH, a long-acting prodrug of parathyroid hormone for hypoparathyroidism, and TransCon CNP, a long-acting prodrug of C-Type Natriuretic Peptide for achondroplasia. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology.